Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
ALS patients experience neuroinflammation and rapid neurodegeneration
Subscribe To Our Newsletter & Stay Updated
